

**Salford Royal NHS Foundation Trust:
Performance in delivering clinical research
Reporting period 1 January 2017 - 31 December 2017**

REC reference	IRAS reference	Name of trial	Target number of patients agreed?	Minimum number of patients agreed	Maximum number of patients agreed	Target date to recruit patients agreed?	Date agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Date the trial closed to recruitment	Total number of study participants recruited	Reason for closure of trial
16/LO/1215	204366	A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAGE-547 injection in the treatment of subjects with super-refractory status epilepticus	Number agreed	2	2	Date agreed	31/05/2017	0	11/07/2017	1	Recruitment finished
15/SC/0165	173920	A single-blinded, randomized, controlled study to evaluate the safety and effectiveness of EVICEL fibrin sealant (human) compared to a hydrogel sealant as an adjunct to sutured dural repair	Number agreed	5	5	Date agreed	31/12/2016	5	29/06/2017	5	Recruitment finished
12/NW/0802	115760	A multinational, multicentre, randomised, double-blind, parallel group, placebo controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod	Number agreed	4	4	Date agreed	28/02/2015	4	09/05/2017	4	Recruitment finished

15/LO/1261	163080	A Phase 3, randomized, double-blind, placebo controlled, parallel group, multi center protocol to evaluate the safety and efficacy of ustekinumab induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis	Number agreed	3	3	Date agreed	28/02/2017	0	13/04/2017	0	Recruitment finished
14/NW/1474	160162	Feasibility study of the antimicrobial hernia repair device for repair of ventral or incisional hernia	Number agreed	5	5	Date agreed	30/09/2016	0	06/02/2017	0	Recruitment finished
16/LO/0586	200579	An open label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have had a suboptimal response to an adequate course of disease-modifying treatment	Number agreed	3	3	Date agreed	31/07/2017	2	24/02/2017	2	Recruitment finished
15/NE/0277	178822	Multicentre, randomised, double-blind, parallel group, active controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide in subjects with relapsing multiple sclerosis: OPTIMUM	Number agreed	5	5	Date agreed	30/06/2015	0	30/01/2017	2	Recruitment finished
15/WS/0219	187482	A Phase 3, randomized, vehicle-controlled, double-blind, multicenter study to evaluate the safety and efficacy of a once-daily CLS001 topical gel versus vehicle administered for 12 weeks to subjects with papulopustular rosacea	Range agreed	4	6	Date agreed	30/09/2016	1	20/03/2017	1	Withdrawn by sponsor

16/WM/0247	202461	APPRECIATE (APREmilast Clinical Treatment Experience in psoriasis): A multi-center, retrospective observational study of real-world experience of psoriasis patients treated with Apremilast in clinical dermatology practice	Range agreed	5	7	Date agreed	31/12/2016	5	30/06/2017	6	Recruitment finished
16/WM/0478	208172	A phase 3 trial comparing the efficacy and safety of LEO 90100 aerosol foam with the aerosol foam vehicle used twice weekly as long-term maintenance therapy in subjects with psoriasis vulgaris.	Number agreed	10	10	Date agreed	30/09/2017	7	19/06/2017	7	Recruitment finished
16/LO/0542	201528	An open-label, Phase 3 study examining the long-term safety, tolerability and efficacy of APL-130277 in levodopa responsive patients with Parkinson's disease complicated by motor fluctuations ("OFF" episodes)	Number agreed	4	4	Date agreed	31/10/2016	2	31/03/2017	2	Recruitment finished
13/LO/1758	136392	A Phase III, randomized, placebo-controlled, parallel-group, double-blind clinical trial to study the efficacy and safety of MK-8931 (SCH 900931) in subjects with amnesic mild cognitive impairment due to Alzheimer's disease (Prodromal AD).	Number agreed	8	8	Date agreed	14/07/2016	8	24/01/2017	9	Recruitment finished
14/SS/1087	164169	A Phase 3b, multi-center, open-label trial to evaluate the long term safety of a titrated Immediate-release selective arginine vasopressin type 2 receptor antagonist (30 mg to 120 mg/day, split dose) in subjects with autosomal	Range agreed	1	5	Date agreed	02/02/2017	3	31/05/2017	3	Recruitment finished

		dominant polycystic kidney disease									
15/NW/0786	189127	A randomized, double blind, double dummy, multicenter, active controlled study to evaluate the efficacy and safety of vedolizumab IV compared to adalimumab SC in subjects with ulcerative colitis	Number agreed	3	3	Date agreed	31/10/2016	0	31/08/2017	0	Recruitment finished
15/LO/1244	183669	A randomized, double-blind, placebo-controlled, multicentre proof of-concept trial of IVA337 in the treatment of diffuse cutaneous systemic sclerosis	Number agreed	4	4	Not available / not agreed			18/09/2017	2	Recruitment finished
15/LO/1681	185104	A double blind, randomized, placebo-controlled trial evaluating safety and efficacy of oral Nintedanib, 150 mg twice daily for 52 weeks in patients with systemic sclerosis	Number agreed	3	3	Date agreed	30/04/2017	1	07/09/2017	1	Recruitment finished
15/YH/0287	174975	An open label study of Dupilumab in patients with atopic dermatitis who participated in previous Dupilumab clinical trials	Number agreed	2	2	Not available / not agreed			25/05/2017	1	Recruitment finished
15/NE/0269	206867	A parallel-Group, double blind long term safety trial of MK-8931 in subjects with Alzheimer's disease. (Protocol No. MK-8931-017- 12) (also known as SCH 900931, P07738)	Number agreed	6	6	Date agreed	31/03/2016	3	28/02/2017	3	Withdrawn by sponsor
16/LO/0702	200919	A randomized, double-blind, parallel-group, multicentre study to demonstrate similar efficacy and to compare safety and immunogenicity of GP2017 and Humira in patients with moderate to severe active rheumatoid arthritis	Number agreed	3	3	Date agreed	20/10/2016	0	28/09/2017	0	Withdrawn by sponsor

17/EM/0006	216496	A parallel group, double-blind, randomized, placebo controlled Phase 3 trial to evaluate the efficacy and safety of ALD403 administered intravenously in patients with chronic migraine	Number agreed	1	1	Date agreed	31/05/2018	1	05/07/2017	1	Withdrawn by sponsor
15/NW/0821	191169	Comparison of Calprotectin levels in stool and rectal mucus in subjects with suspected or confirmed inflammatory bowel disease	Number agreed	114	114	Date agreed	31/08/2016	8	01/06/2017	12	Recruitment finished
15/SS/0148	181087	A Phase 3 multi center, randomized, double blind, placebo controlled, parallel group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer's disease	Number agreed	7	7	Date agreed	31/12/2018	5	26/04/2017	5	Withdrawn by sponsor
16/EE/0357	206501	Phase IV clinical trial is to evaluate the safety and efficacy of opicapone (a new COMT inhibitor) on the 'wearing-off' phenomenon of patients with idiopathic Parkinson's disease treated with levodopa plus dopa decarboxylase inhibitor	Range agreed	3	6	Date agreed	30/11/2017	6	22/12/2017	6	Recruitment finished
13/NW/0496	115372	A randomized, double-blind, placebo controlled, parallel group, multi center trial of pregabalin as adjunctive therapy in paediatric and adult subjects with primary generalised tonic clonic seizures	Number agreed	2	2	Date agreed	10/10/2017	3	10/10/2017	3	Recruitment finished
14/LO/1514	150924	An open label study to assess the safety and efficacy of COR'003 (2S, 4RKetoconazole) in the treatment of endogenous Cushing's	Range agreed	1	2	Date agreed	31/07/2016	0	12/07/2017	0	Recruitment finished

		syndrome									
16/SS/0134	199690	A phase 1B multicentre, open-label study to evaluate the safety and tolerability and determine the maximum tolerated dose of PF-05230907 in subjects with intracerebral haemorrhage (ICH)	Number agreed	1	1	Not available / not agreed			17/11/2017	0	Withdrawn by sponsor